In8bio Inc (INAB)

US · Healthcare · Biotechnology

$1.07+5.94%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit

$-4.8M

EPS

$-0.25

EPS estimate

$-0.61

EPS came in at -0.25 against a street estimate of -0.61 — a beat of 59.0%.

Market cap

$10.8M

Forward P/E

0.0

P/B

0.58

Book value

$1.86

EPS (TTM)

$-1.31

52-week high

$2.73

52-week low

$0.88

50-day MA

$1.19

200-day MA

$1.60

Beta

0.29

Analysts rate In8bio Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $6.25.

Insiders

7.58%

Institutions

38.45%

Fund	Stake
Alyeska Investment Group, L.P.	9.58%
Franklin Templeton Inc	9.28%
683 Capital Management LLC	7.35%
Stonepine Capital Management Llc	6.73%
Vanguard Capital Management, LLC	0.90%
Geode Capital Management, LLC	0.88%
BIOS CAPITAL MANAGEMENT, LP	0.82%
Vanguard Fiduciary Trust Co	0.44%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for In8bio Inc — free to start.

Data updated 2026-09-18.